Zhitong Financial App News, Hanson Pharmaceuticals (03692.HK) issued an announcement. On September 29, 2026, the Group re-submitted a marketing license application (MAA) for the innovative drug ametinib in the European Union (EMA), and on October 7, 2026, the EMA confirmed acceptance of the new MAA and officially initiated a centralized approval process. The indications are: (i) advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 missing or exon 21 (L858R) replacement mutations (NSCLC) adult patients First-line treatment, and (ii) treatment of adult patients with advanced NSCLC who are positive for the EGFR T790M mutation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.